Rinvoq is now approved for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 years old and older whose disease did not respond to previous treatment.
Pfizer’s Xeljanz is now approved for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin, an epithelial cytokine.